|Mr. Anthony S. Marucci M.B.A.||Founder, Pres, CEO & Director||1.18M||20.16k||1962|
|Dr. Tibor Keler||Founder, Chief Scientific Officer & Exec. VP||748.51k||N/A||1959|
|Mr. Sam Martin||Sr. VP, CFO, Sec. & Treasurer||619.35k||1.39M||1971|
|Mr. Freddy A. Jimenez Esq.||Sr. VP & Gen. Counsel||579.7k||N/A||1969|
|Dr. Diane C. Young M.D.||Sr. VP & Chief Medical Officer||636k||149.78k||1957|
|Prof. Joseph P. Schlessinger Ph.D.||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||1945|
|Ms. Sarah Cavanaugh||Sr. VP of Corp. Affairs & Admin.||N/A||N/A||1975|
|Patrick Till||Sr. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Dr. Ronald A. Pepin||Chief Bus. Officer & Sr. VP||N/A||N/A||1956|
|Ms. Elizabeth Crowley||Chief Product Devel. Officer & Sr. VP||N/A||N/A||1972|
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Celldex Therapeutics, Inc.’s ISS governance QualityScore as of 1 June 2022 is 2. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 1; Compensation: 5.